# US 2026/0311325 A1 · Real-time adequacy assessment of human biopsy sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0311325 A1
- Document ID: US20260311325A1
- Status: Published application
- Kind: A1
- Application number: 19/463,809
- Filed: 2026-01-29
- Published: 2026-10-08
- Earliest claimed: 2025-01-30
- Assignees: Kendall Square Laboratories, Inc.
- Applicants: Kendall Square Laboratories, Inc.
- Inventors: Vijaya Kolachalama
- Web page: https://patentgrep.com/patent/US20260311325A1

## CPC

- G06T 7/0012: {Biomedical image inspection}
- G06T 2207/20081: Training; Learning
- G06T 2207/30024: Cell structures in vitro; Tissue sections in vitro
- G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL

## Abstract

A method for assessing the adequacy of a biopsy sample is provided. The method includes generating an image of a biopsy sample. The method includes providing the image of the biopsy sample to an evaluation engine. The method includes receiving a report from the evaluation engine, wherein the report comprises an indication of the adequacy of the biopsy sample. The method includes making a determination, based on the report, on whether the biopsy sample is adequate.

## Claims

### Claim 1

A method for assessing the adequacy of a biopsy sample, the method comprising:
generating an image of a biopsy sample;
providing the image of the biopsy sample to an evaluation engine;
receiving a report from the evaluation engine, wherein the report comprises an indication of the adequacy of the biopsy sample; and
making a determination, based on the report, on whether the biopsy sample is adequate.

### Claim 2 (depends on 1)

The method of claim 1, further comprising, as a result of making a determination, based on the report, on whether the biopsy sample is adequate, determining whether a further biopsy sample is needed.

### Claim 3 (depends on 1)

The method of claim 1, wherein the report is received after providing the image of the biopsy sample to an evaluation engine within two minutes.

### Claim 4 (depends on 1)

The method of claim 1, wherein the report includes a textual description of the biopsy sample.

### Claim 5

A method for assessing the adequacy of a biopsy sample, the method comprising:
receiving an image of a biopsy sample;
processing the image of the biopsy sample using a machine learning (ML) and/or artificial intelligence (AI) based model to generate a report, wherein the report comprises an indication of the adequacy of the biopsy sample; and
providing the report to a user.

### Claim 6 (depends on 5)

The method of claim 5, wherein the report comprises information on one or more isolated elements of the biopsy sample including a cortex.

### Claim 7 (depends on 6)

The method of claim 6, wherein the report comprises one or more biopsy-level metrics including a percentage of the cortex in relation to the overall biopsy sample.

### Claim 8 (depends on 5)

The method of claim 5, wherein the ML and/or AI model comprises a deep neural network.

### Claim 9 (depends on 5)

The method of claim 5, wherein the report is provided to the user after receiving the image of the biopsy sample within two minutes.

### Claim 10 (depends on 5)

The method of claim 5, wherein the report includes a textual description of the biopsy sample.

### Claim 11

A computing device for assessing the adequacy of a biopsy sample, the computing device comprising:
processing circuitry configured to:
generate an image of a biopsy sample;
provide the image of the biopsy sample to an evaluation engine;
receive a report from the evaluation engine, wherein the report comprises an indication of the adequacy of the biopsy sample; and
make a determination, based on the report, on whether the biopsy sample is adequate.

### Claim 12

A computing device for assessing the adequacy of a biopsy sample, the computing device comprising:
processing circuitry configured to:
receive an image of a biopsy sample;
process the image of the biopsy sample using a machine learning (ML) and/or artificial intelligence (AI) based model to generate a report, wherein the report comprises an indication of the adequacy of the biopsy sample; and
provide the report to a user.
